Capecitabine-[National Institute for 3-Year Delay?]
Capecitabine [aka Xeloda] has been approved for use
in North America [USA & Canada] in recurrent or metastatic breast cancer since 2000 at the latest.
Adriamycin-based combinations followed by a taxane
are the standard of care; capecitabine should be an obvious
Another point is that Xeloda is a chemically trivial
modification of 5-fluorouracil, formulated to enhance
tumor targeting and binding.
Is this recommendation really a mark of clinical excellence,
or a long-deferred catch-up in best practice?
Competing interests: No competing interests